SI-BONE, Inc. - Common Stock (SIBN)

It's off to a roaring start as far as the financial year is concerned.

SiBone (NASDAQ:SIBN) raised its full-year 2026 outlook after reporting double-digit revenue growth in the first quarter, with management pointing to new product launches, expanding physician adoption, international momentum and a proposed Medicare reimbursement change as key drivers for the year ahe

SI-Bone (SIBN) Q1 2026 Earnings Transcript

SI-BONE (SIBN) Q4 2025 Earnings Call Transcript

Take-up of the company's wares among physicians is rising significantly.

SI-BONE (SIBN) beats Q3 2025 earnings and revenue estimates, prompting a stock surge and an upward revision to its full-year guidance.

In a significant move to avert a potential financial crisis, the Federal Reserve announced in October 2025 its decision to halt its three-year Quantitative Tightening (QT) program and cut interest rates. This decisive action comes amidst growing concerns over tightening liquidity in money markets and recent market strains, signaling that

SI-BONE INC reports mixed Q2 2025 results with revenue slightly below estimates but beats on EPS, driving a positive market reaction. Strong growth and raised guidance signal confidence.

Four companies experienced significant short-term rallies following better-than-expected earnings; can they maintain momentum going forward?